Summary

A prespecified integrated analysis of two Phase 3 clinical trials demonstrates that the monoclonal antibody ustekinumab reduces radiographic progression of joint disease in patients with active psoriatic arthritis. This article presents the integrated analysis of the two Phase 3 Multicenter, Randomised, Double-Blind, Placebo-Controlled Trials of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriasis Arthritis [PSUMMIT I and II; NCT01009086; NCT01077362].